Patents by Inventor Luis Rosado
Luis Rosado has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11470697Abstract: Disclosed is an electrical dimmer that upon activation sends a forward-phase modulated test power pulse to a connected load, receives from the load a response pulse, compares the width of the two pulses, and, depending upon the results of the comparison, operates in either forward- or reverse-phase modulation. The dimmer may respond to an intensity target by setting a pulse-width modulation duty cycle, the setting based on an intensity-translation curve. The translation curve may be based on a mapping between luminance and human visual perception of brightness. Some dimmers support a minimum intensity setting, and some dimmers configure themselves to the frequency of the incoming alternating-current power source.Type: GrantFiled: September 15, 2020Date of Patent: October 11, 2022Assignee: Boca Flasher, Inc.Inventor: Luis Rosado
-
Publication number: 20170332690Abstract: The present invention is directed to an infant formula specially designed to reduce episodes of regurgitation, colic and constipation that occur in infants fed on infant formula. The composition represents a needed improvement to the art because it contains in a single composition substances that simultaneously addresses these three problems.Type: ApplicationFiled: March 6, 2017Publication date: November 23, 2017Applicant: Nucitec S.A. de C.V.Inventors: Jorge Luis ROSADO LORIA, Miguel Angel DUARTE-VÁZQUEZ
-
Patent number: 9591872Abstract: The present invention is directed to an infant formula specially designed to reduce episodes of regurgitation, colic and constipation that occur in infants fed on infant formula. The composition represents a needed improvement to the art because it contains in a single composition substances that simultaneously addresses these three problems.Type: GrantFiled: July 26, 2012Date of Patent: March 14, 2017Assignee: Nucitec S.A. de C.V.Inventors: Jorge Luis Rosado Loria, Miguel Angel Duarte-Vázquez
-
Patent number: 9492466Abstract: The present disclosure provides methods of treating, ameliorating, or preventing immune disorders, allergic disorders, or inflammatory disorders, or combinations thereof, or providing hepatoprotection in subject. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a ?-hydroxy-?-aminophosphonate or ?-amino-?-aminophosphonate.Type: GrantFiled: March 14, 2013Date of Patent: November 15, 2016Assignee: Nucitec S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Jorge Luis Rosado Loria, Miguel Angel Duarte Vazquez, José Mario Ordóñez Palacios, Jorge Alberto Reyes Esparza, Maria de Lourdes Rodriguez Fragoso
-
Publication number: 20150245644Abstract: The present disclosure is related to the obtaining of a nutritional formula for the feeding of preterm born infants. The formula comprises a mixture of casein; whey milk protein; alphalactalbumin; beta casein A2 protein, lactose; palmitic acid in beta position; non digestible oligosaccharides; long chain polyunsaturated fatty acids (LC PUFAS); nucleotides; vitamins and minerals; inositol, choline, taurine and carnitine in concentrations sufficient enough to satisfy nutritional requirements of premature children, besides being better-tolerated.Type: ApplicationFiled: May 2, 2013Publication date: September 3, 2015Applicant: NUCITEC, S.A. DE C.V.Inventors: Jorge Luis Rosado Loria, Miguel Angel Duarte Vázquez
-
Publication number: 20150237902Abstract: An infant formula specially designed for covering nutrition necessities of infants between 0 and 36 months of life is described, which reduces the intolerance problems related to the consumption of infant formulas currently found in the art.Type: ApplicationFiled: May 2, 2013Publication date: August 27, 2015Applicant: Nucitec, S.A. DE C.V.Inventors: Jorge Luis Rosado Loria, Miguel Angel Duarte Vázquez
-
Patent number: 9056134Abstract: The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals, endocrinology and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an anti-hyperglycemic compound for use in the treatment and/or prevention of cardiometabolic risk factors of Metabolic Syndrome and treatment and/or prevention of Metabolic Syndrome. The present invention provides for the use of such compositions in the manufacture of products for treatment and/or prevention of Metabolic Syndrome. The biguanide metformin of the composition could be present in extended release form allowing its use together with the other drugs in a single dosage form at low dose. This combination of drugs in a single daily dosage greatly improves compliance and adherence to treatment which is a critical factor for treating patients with Metabolic Syndrome.Type: GrantFiled: July 21, 2011Date of Patent: June 16, 2015Assignee: NUCITEC S.A. DE C.V.Inventors: Miguel Angel Duarte-Vazquez, Sandra Garcia Padilla, Jorge Luis Rosado
-
Publication number: 20140107079Abstract: The present disclosure provides methods of treating, ameliorating, or preventing immune disorders, allergic disorders, or inflammatory disorders, or combinations thereof, or providing hepatoprotection in subject. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a ?-hydroxy-?-aminophosphonate or ?-amino-?-aminophosphonate.Type: ApplicationFiled: March 14, 2013Publication date: April 17, 2014Applicant: Nucites S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Jorge Luis Rosado Loria, Miguel Angel Duarte Vazquez, José Mario Ordóñez Palacios, Jorge Alberto Reyes Esparza, Maria de Lourdes Rodriguez Fragoso
-
Publication number: 20130314920Abstract: Thermally radiating heat sinks are soldered directly beneath individual LEDs and other heat generating electronic components on the opposite side of an FR4 circuit board and thermally coupled to the heat source through multiple micro-vias. The micro-vias are filled with solder in order to increase the thermal transmission of heat energy through the circuit board to the heat sinks The circuit board thickness is minimized to further reduce the thermal resistance of the transmission path. The method employed facilitates the heat transfer away from high-powered LEDs and other heat generating circuitry without spreading the heat energy to thermally sensitive electronic circuits and without the need for expensive substrates commonly employed to dissipate heat in electronic circuits. The method is adapted for LED lighting circuits and preferably to industry standard bulb sizes such as MR11, MR16, R20, PAR30, PAR38, and PAR56.Type: ApplicationFiled: May 25, 2012Publication date: November 28, 2013Inventors: Myung Ho Park, Luis Rosado
-
Patent number: 8536362Abstract: The present invention provides ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.Type: GrantFiled: March 22, 2012Date of Patent: September 17, 2013Assignee: Nucitec S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Miguel Ångel Duarte Vázquez, Jorge Luis Rosado Loria
-
Publication number: 20130189398Abstract: The present invention is directed to an infant formula specially designed to reduce episodes of regurgitation, colic and constipation that occur in infants fed on infant formula. The composition represents a needed improvement to the art because it contains in a single composition substances that simultaneously addresses these three problems.Type: ApplicationFiled: July 26, 2012Publication date: July 25, 2013Applicant: Nucitec S.A. de C.V.Inventors: Jorge Luis ROSADO LORIA, Miguel Angel Duarte-Vázquez
-
Publication number: 20130115336Abstract: An infant formula was developed. This formula was specially designed for infants with history of allergy to cow's milk proteins, Which normally occurs in infants fed with infant formula. The invention represents a novelty, because in addition to its unique composition, the formula of the invention is more effective than the formulas commonly used to address the problem of protein allergy, and also it contains substances that support a proper physical and mental development of the infant.Type: ApplicationFiled: September 28, 2012Publication date: May 9, 2013Inventors: Jorge Luis Rosado Loria, Miguel Angel Duarte-Vázquez
-
Publication number: 20130079308Abstract: The present invention provides ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.Type: ApplicationFiled: March 22, 2012Publication date: March 28, 2013Applicant: Nucitec S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Miguel Ångel Duarte Vázquez, Jorge Luis Rosado Loria
-
Patent number: 8324185Abstract: Current invention is related to the pharmaceutical industry in general and to the industry of the manufacture of pharmaceutical products for weight reduction and hyperlipidemia treatment. The advantages of the current invention respect of the similar of the state of the art are that in the present invention side effects normally produced by the consumption of lipase inhibitors are eliminated; optimizing both the lipase inhibitor component and the fat-trapping; with the adequate composition of each one of the components and with very small amounts of each one. The invention consists of a composition for the treatment of the obesity and hyperlipidemia, characterized by comprising in combination a lipase inhibitor and a fat-trapping component.Type: GrantFiled: July 18, 2005Date of Patent: December 4, 2012Assignee: Nucitec, S.A. DF C.V.Inventors: Jorge Luis Rosado Loria, Miguel Angel Duarte Vàzquez, Sandra García Padilla
-
Patent number: 8178515Abstract: The present invention provides ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.Type: GrantFiled: October 8, 2009Date of Patent: May 15, 2012Assignee: Nucitec S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Miguel Angel Duarte-Vazquez, Jorge Luis Rosado Loria
-
Publication number: 20120095059Abstract: The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or rosiglitazone), at least one sulfonylurea (e.g., glimepiride), and at least one biguanide (e.g., metformin or a pharmaceutically acceptable salt or ester thereof, such as metformin HCl). The present invention also provides methods of treating type II diabetes and related disorders in a mammal, suitably a human, by administering to a mammal in need thereof one or more of the compositions of the present invention.Type: ApplicationFiled: April 13, 2011Publication date: April 19, 2012Inventors: Jorge Luis Rosado, Miguel Angel Duarte-Vázquez
-
Publication number: 20120021049Abstract: The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals, endocrinology and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an anti-hyperglycemic compound for use in the treatment and/or prevention of cardiometabolic risk factors of Metabolic Syndrome and treatment and/or prevention of Metabolic Syndrome. The present invention provides for the use of such compositions in the manufacture of products for treatment and/or prevention of Metabolic Syndrome. The biguanide metformin of the composition could be present in extended release form allowing its use together with the other drugs in a single dosage form at low dose. This combination of drugs in a single daily dosage greatly improves compliance and adherence to treatment which is a critical factor for treating patients with Metabolic Syndrome.Type: ApplicationFiled: July 21, 2011Publication date: January 26, 2012Applicant: Nucitec S.A. de C.V.Inventors: Miguel Angel Duarte-Vázquez, Sandra Garcia Padilla, Jorge Luis Rosado
-
Publication number: 20100234442Abstract: The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and cardiology. In one aspect, the invention provides compositions comprising enalapril and simvastatin for use in methods for the treatment and/or prevention of cardiovascular disease, and to the use of such compositions in the manufacture of products for such treatment and/or prevention. In another aspect, the invention provides methods for the treatment and/or prevention of cardiovascular disease using compositions comprising enalapril, simvastatin and acetylsalicylic acid. The compositions and methods of the invention are useful in the treatment and prevention of cardiovascular disease in a variety of animals, particularly humans.Type: ApplicationFiled: March 12, 2010Publication date: September 16, 2010Applicant: Nucitec S.A. de C.V.Inventors: Miguel Angel Duarte-Vazquez, Jorge Luis Rosado Loria
-
Publication number: 20100087400Abstract: The present invention provides ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.Type: ApplicationFiled: October 8, 2009Publication date: April 8, 2010Applicant: Nucitec S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Miguel Angel Duarte Vázquez, Jorge Luis Rosado Loria
-
Publication number: 20090197831Abstract: Current invention is related to the pharmaceutical industry in general and to the industry of the manufacture of pharmaceutical products for weight reduction and hyperlipidemia treatment. The advantages of the current invention respect of the similar of the state of the art are that in the present invention side effects normally produced by the consumption of lipase inhibitors are eliminated; optimizing both the lipase inhibitor component and the fat-trapping; with the adequate composition of each one of the components and with very small amounts of each one. The invention consists of a composition for the treatment of the obesity and hyperlipidemia, characterized by comprising in combination a lipase inhibitor and a fat-trapping component.Type: ApplicationFiled: July 18, 2005Publication date: August 6, 2009Inventors: Jorge Luis Rosado Loria, Miguel Angel Duarte Vazquez, Sandra Garcia Padilla